Recent Transactions

Advised I Squared Capital on the contribution of Pinnacle Midstream, its Delaware Basin Midstream Company, to EagleClaw Midstream as part of the formation of a leading Delaware Basin Midstream Partnership with EagleClaw Midstream and Blackstone Energy Partners

Advised Canopy Growth on a C$5bn investment by Constellation Brands. As consideration for the investment, Constellation received newly issued Canopy common shares and common share purchase warrants

Advised Osaka Gas, a Japanese utility, on the acquisition of 35% of Sabine Oil & Gas’s interest in oil and gas properties located primarily in Harrison and Panola Counties, Texas

Advised Willbros Group, Inc., a specialty energy infrastructure contractor serving the power and oil & gas industries, on its sale to Primoris Services Corporation

Advised Total System Services, a provider of payment processing, merchant services and related payment services, on acquiring Cayan, a payment technology company focused on integrated solutions and merchant acquiring

Advised Energy Corporation of America, a natural gas producer focused on the Marcellus Shale, on the sale of substantially all its gas production and midstream assets to Greylock Energy, an affiliate of ArcLight Capital Partners

Advised Equiniti Group plc, a UK based specialist technology outsourcer providing non-discretionary payment and administration services, on the acquisition of Wells Fargo's Shareowner Services business, and acted as joint sponsor to Equiniti's associated £122 million rights issue

Advised Natural Resource Partners L.P., a publicly-traded master limited partnership that owns, manages and leases mineral properties in the United States, on a series of recapitalization transactions including the extension of NRP’s near-term debt maturities and the issuance of $250mm of new preferred equity capital to funds managed by Blackstone Tactical Opportunities and from several affiliates of GoldenTree Asset Management L.P.

Advised Palatin Technologies, Inc. on the exclusive licensing of North American rights to develop and commercialize RekyndaTM (bremelanotide), an investigational product designed for on-demand treatment for hypoactive sexual desire disorder in pre-menopausal women, to AMAG Pharmaceuticals, Inc.

Advised the Special Committee of the Board of Directors of Concordia International, a diverse, international specialty pharmaceutical company focused on generic and legacy pharmaceutical products and orphan drugs, on its strategic review process

Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on its sale of assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited) for £603m (c.$775m)